Cargando…
Hyperkalemia: pathophysiology, risk factors and consequences
There have been significant recent advances in our understanding of the mechanisms that maintain potassium homoeostasis and the clinical consequences of hyperkalemia. In this article we discuss these advances within a concise review of the pathophysiology, risk factors and consequences of hyperkalem...
Autores principales: | , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Oxford University Press
2019
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6892421/ https://www.ncbi.nlm.nih.gov/pubmed/31800080 http://dx.doi.org/10.1093/ndt/gfz206 |
_version_ | 1783476027274559488 |
---|---|
author | Hunter, Robert W Bailey, Matthew A |
author_facet | Hunter, Robert W Bailey, Matthew A |
author_sort | Hunter, Robert W |
collection | PubMed |
description | There have been significant recent advances in our understanding of the mechanisms that maintain potassium homoeostasis and the clinical consequences of hyperkalemia. In this article we discuss these advances within a concise review of the pathophysiology, risk factors and consequences of hyperkalemia. We highlight aspects that are of particular relevance for clinical practice. Hyperkalemia occurs when renal potassium excretion is limited by reductions in glomerular filtration rate, tubular flow, distal sodium delivery or the expression of aldosterone-sensitive ion transporters in the distal nephron. Accordingly, the major risk factors for hyperkalemia are renal failure, diabetes mellitus, adrenal disease and the use of angiotensin-converting enzyme inhibitors, angiotensin receptor blockers or potassium-sparing diuretics. Hyperkalemia is associated with an increased risk of death, and this is only in part explicable by hyperkalemia-induced cardiac arrhythmia. In addition to its well-established effects on cardiac excitability, hyperkalemia could also contribute to peripheral neuropathy and cause renal tubular acidosis. Hyperkalemia—or the fear of hyperkalemia—contributes to the underprescription of potentially beneficial medications, particularly in heart failure. The newer potassium binders could play a role in attempts to minimize reduced prescribing of renin–angiotensin inhibitors and mineraolocorticoid antagonists in this context. |
format | Online Article Text |
id | pubmed-6892421 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2019 |
publisher | Oxford University Press |
record_format | MEDLINE/PubMed |
spelling | pubmed-68924212019-12-10 Hyperkalemia: pathophysiology, risk factors and consequences Hunter, Robert W Bailey, Matthew A Nephrol Dial Transplant Reviews There have been significant recent advances in our understanding of the mechanisms that maintain potassium homoeostasis and the clinical consequences of hyperkalemia. In this article we discuss these advances within a concise review of the pathophysiology, risk factors and consequences of hyperkalemia. We highlight aspects that are of particular relevance for clinical practice. Hyperkalemia occurs when renal potassium excretion is limited by reductions in glomerular filtration rate, tubular flow, distal sodium delivery or the expression of aldosterone-sensitive ion transporters in the distal nephron. Accordingly, the major risk factors for hyperkalemia are renal failure, diabetes mellitus, adrenal disease and the use of angiotensin-converting enzyme inhibitors, angiotensin receptor blockers or potassium-sparing diuretics. Hyperkalemia is associated with an increased risk of death, and this is only in part explicable by hyperkalemia-induced cardiac arrhythmia. In addition to its well-established effects on cardiac excitability, hyperkalemia could also contribute to peripheral neuropathy and cause renal tubular acidosis. Hyperkalemia—or the fear of hyperkalemia—contributes to the underprescription of potentially beneficial medications, particularly in heart failure. The newer potassium binders could play a role in attempts to minimize reduced prescribing of renin–angiotensin inhibitors and mineraolocorticoid antagonists in this context. Oxford University Press 2019-12 2019-12-04 /pmc/articles/PMC6892421/ /pubmed/31800080 http://dx.doi.org/10.1093/ndt/gfz206 Text en © The Author(s) 2019. Published by Oxford University Press on behalf of ERA-EDTA. http://creativecommons.org/licenses/by/4.0/ This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted reuse, distribution, and reproduction in any medium, provided the original work is properly cited. |
spellingShingle | Reviews Hunter, Robert W Bailey, Matthew A Hyperkalemia: pathophysiology, risk factors and consequences |
title | Hyperkalemia: pathophysiology, risk factors and consequences |
title_full | Hyperkalemia: pathophysiology, risk factors and consequences |
title_fullStr | Hyperkalemia: pathophysiology, risk factors and consequences |
title_full_unstemmed | Hyperkalemia: pathophysiology, risk factors and consequences |
title_short | Hyperkalemia: pathophysiology, risk factors and consequences |
title_sort | hyperkalemia: pathophysiology, risk factors and consequences |
topic | Reviews |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6892421/ https://www.ncbi.nlm.nih.gov/pubmed/31800080 http://dx.doi.org/10.1093/ndt/gfz206 |
work_keys_str_mv | AT hunterrobertw hyperkalemiapathophysiologyriskfactorsandconsequences AT baileymatthewa hyperkalemiapathophysiologyriskfactorsandconsequences |